ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΚΑΙ ΒΙΟΜΗΧΑΝΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ, ΧΗΜΙΚΩΝ ΚΑΙ ΚΑΛΛΥΝΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ LAVIPHARM Α.Ε. financials
ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΚΑΙ ΒΙΟΜΗΧΑΝΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ, ΧΗΜΙΚΩΝ ΚΑΙ ΚΑΛΛΥΝΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ LAVIPHARM Α.Ε.
Country: GR Reporting currency: EUR Latest annual report: 2024-12-31
LEI:
213800USC69CRPRGWJ15 Financial statements
(EUR, as reported — unscaled; 111 line items across 2 annual periods)
| Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | €52.9M | €47.8M |
| Cost of sales | €27.9M | €25.7M |
| Gross profit | €25.1M | €22.1M |
| Distribution costs | €13.0M | €11.9M |
| Administrative expenses | €7.9M | €6.2M |
| Operating profit (EBIT) | €5.5M | €5.2M |
| Net finance income / (cost) | -€1.9M | -€2.0M |
| Finance costs | €2.1M | €2.2M |
| Income tax expense | -€5.1M | €1.2M |
| Profit for the year | €9.0M | €1.9M |
| — attributable to owners | €9.0M | €1.9M |
| — attributable to NCI | -€3.0K | -€2.0K |
| Total comprehensive income | €8.9M | €1.8M |
| Cash flow statement | ||
| Cash generated from operations | €12.3M | €9.4M |
| Net cash from operating activities | €4.6M | €284.0K |
| Net cash from investing activities | -€9.5M | -€3.5M |
| Net cash from financing activities | €2.2M | -€6.6M |
| Proceeds from borrowings | €34.2M | €47.6M |
| Repayments of borrowings | €31.5M | €50.8M |
| Balance sheet | ||
| Total assets | €125.5M | €114.8M |
| Non-current assets | €80.5M | €69.1M |
| Property, plant & equipment | €10.8M | €8.5M |
| Right-of-use assets | €10.6M | €11.1M |
| Current assets | €45.0M | €45.7M |
| Inventories | €19.5M | €14.8M |
| Trade & other receivables | €18.3M | €21.7M |
| Total equity | €53.0M | €42.8M |
| — attributable to owners | €53.0M | €42.7M |
| Non-controlling interests | -€10.0K | €33.0K |
| Non-current liabilities | €33.4M | €36.2M |
| Long-term borrowings | €12.2M | €12.7M |
| Lease liabilities (non-current) | €10.2M | €11.0M |
| Current liabilities | €39.1M | €35.8M |
| Lease liabilities (current) | €905.0K | €684.0K |
| Trade & other payables | €26.5M | €26.9M |
| Derived metrics | ||
| Free cash flow | -€5.0M | -€3.8M |
| Operating margin | 10.5% | 10.8% |
| Net margin | 17.0% | 3.9% |
| Return on equity | 17.0% | 4.4% |
| Cash conversion ratio | 0.52× | 0.15× |
| Capex coverage | 0.48× | 0.07× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -€5.3M | -€4.9M |
| Adjustments For Decrease Increase In Other Assets | -€10.0K | €35.0K |
| Adjustments For Decrease Increase In Trade Account Receivable | -€1.3M | -€6.2M |
| Adjustments For Depreciation and Amortisation Expense | €4.6M | €4.2M |
| Adjustments For Fair Value Gains Losses | €0 | -€91.0K |
| Adjustments For Finance Costs | €2.1M | €2.2M |
| Adjustments For Finance Income | €156.0K | €270.0K |
| Adjustments For Gain Loss On Disposal of Investments In Subsidiaries Joint Ventures and Associates | €0 | €0 |
| Adjustments For Gains Losses On Fair Value Adjustment Investment Property | €157.0K | €367.0K |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €0 | €0 |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Trade and Other Receivables | -€317.0K | €0 |
| Adjustments For Increase Decrease In Trade Account Payable | €137.0K | €2.6M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | €0 | -€405.0K |
| Adjustments For Provisions | €1.3M | €259.0K |
| Basic Earnings Loss Per Share From Continuing Operations | €515.00 | €118.00 |
| Basic Earnings Loss Per Share From Discontinued Operations | €19.00 | €-6.00 |
| Cash Flows From Used In Financing Activities Discontinued Operations | -€658.0K | -€1.9M |
| Cash Flows From Used In Investing Activities Discontinued Operations | -€11.0K | -€68.0K |
| Cash Flows From Used In Operating Activities Discontinued Operations | €888.0K | €1.5M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €0 | €0 |
| Cash Outflow For Leases | €928.0K | €1.1M |
| Comprehensive Income Attributable To Noncontrolling Interests | -€3.0K | -€2.0K |
| Comprehensive Income Attributable To Owners of Parent | €9.0M | €1.8M |
| Current Assets Other Than Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | €1.6M | €683.0K |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €10.6M | €8.0M |
| Current Financial Assets | €0 | €3.0K |
| Current Tax Liabilities | €245.0K | €242.0K |
| Deferred Tax Assets | €6.5M | €1.3M |
| Diluted Earnings Loss Per Share From Continuing Operations | €514.00 | €117.00 |
| Diluted Earnings Loss Per Share From Discontinued Operations | €19.00 | €-6.00 |
| Equity and Liabilities | €125.5M | €114.8M |
| Finance Income | €157.0K | €270.0K |
| Gains Losses On Fair Value Adjustment Investment Property | €157.0K | €367.0K |
| Gains Losses On Financial Assets At Fair Value Through Profit Or Loss | €0 | €1.0K |
| Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €0 | €0 |
| Income Taxes Paid Refund Classified As Operating Activities | €172.0K | €261.0K |
| Increase Decrease In Cash and Cash Equivalents | -€2.7M | -€9.8M |
| Increase Decrease Through Appropriation of Retained Earnings | €0 | — |
| Increase Decrease Through Changes In Ownership Interests In Subsidiaries That Do Not Result In Loss of Control | -€112.0K | — |
| Increase Decrease Through Foreign Exchange Financial Assets | €0 | €0 |
| Increase Decrease Through Sharebased Payment Transactions | €1.4M | €635.0K |
| Increase Decrease Through Transfer To Statutory Reserve | €0 | €0 |
| Increase Decrease Through Transfers and Other Changes Equity | €0 | — |
| Intangible Assets Other Than Goodwill | €49.7M | €44.5M |
| Interest Paid Classified As Operating Activities | €1.9M | €1.9M |
| Interest Received Classified As Investing Activities | €156.0K | €255.0K |
| Investment Property | €2.8M | €2.7M |
| Investments In Subsidiaries | €0 | €0 |
| Issued Capital | €50.6M | €50.4M |
| Liabilities | €72.5M | €72.0M |
| Liabilities Included In Disposal Groups Classified As Held For Sale | €900.0K | €0 |
| Miscellaneous Other Operating Expense | €238.0K | €475.0K |
| Miscellaneous Other Operating Income | €2.1M | €1.6M |
| Noncurrent Financial Assets | €2.0K | €1.0M |
| Noncurrent Financial Liabilities | €10.1M | €11.4M |
| Noncurrent Provisions For Employee Benefits | €947.0K | €1.1M |
| Other Adjustments For Noncash Items | €1.4M | €635.0K |
| Other Comprehensive Income | -€28.0K | -€46.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | -€28.0K | -€46.0K |
| Other Inflows Outflows of Cash Classified As Investing Activities | €0 | €0 |
| Other Noncurrent Assets | €75.0K | €82.0K |
| Other Provisions | €0 | €50.0K |
| Other Reserves | €19.1M | €17.6M |
| Proceeds From Disposals of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €0 | €405.0K |
| Profit Loss From Continuing Operations | €8.7M | €2.0M |
| Profit Loss From Discontinued Operations | €315.0K | -€101.0K |
| Purchase of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €9.6M | €4.0M |
| Research and Development Expense | €631.0K | €430.0K |
| Retained Earnings | -€23.9M | -€32.6M |
| Share Premium | €7.2M | €7.4M |
Methodology
Every line item above is a fact tagged in ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΚΑΙ ΒΙΟΜΗΧΑΝΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ, ΧΗΜΙΚΩΝ ΚΑΙ ΚΑΛΛΥΝΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ LAVIPHARM Α.Ε.'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.